Stress-induced Sleep Deficits and a Complementary Therapy — Sleep-Aid  

Insomnia Due to Anxiety and Fear Clinical Trial

Official title: Stress-, Anxiety-, and Cellphone Use-induced Sleep Deficits and Psychological Conditions During the Pandemic and a Potential Complementary Therapy

Status Completed

Clinical Trial Summary

The COVID-19 pandemic and social isolation order induced stress/anxiety as well as cellphone dependence. As a result, sleep disruption and mental distress became major health concerns. Gamma-aminobutyric acid type-A receptor (GABAAR) is one of the key players in modulating sleep. Dihydromyricetin (DHM), an herbal compound, plays a role in GABAAR modulation and mitigating anxiety. The investigators' partner in China obtained 288 participants who completed the online survey to gain insight into how stress/anxiety and time spent on cellphones affected sleep and mood. The participants were then enrolled in a randomized placebo-controlled double-blind study to assess the effects of DHM on sleep and improvement on stress/anxiety and cellphone using time.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Insomnia Due to Anxiety and Fear
• Sleep Deprivation

• NCT number: NCT05280561
• Study type: Interventional
• Source: University of Southern California
• Status: Completed
• Phase: N/A
• Start date: July 25, 2021
• Completion date: November 3, 2022